Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis
Abstract The clinical data on the biologic disease-modifying antirheumatic drug (bDMARD) use in late-onset ankylosing spondylitis (LOAS) is limited. Thus, this study aimed to evaluate the drug efficacy and retention rate of bDMARDs in LOAS and compare it to young-onset ankylosing spondylitis (YOAS)....
Guardado en:
Autores principales: | Se Hee Kim, Hae-Rim Kim, Sang-Heon Lee, Kichul Shin, Hyoun-Ah Kim, Hong Ki Min |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2394faec976d44bc8e71473bf6d4cc53 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Management of ankylosing spondylitis with infliximab
por: Éric Toussirot, et al.
Publicado: (2009) -
Efficacy and safety of adalimumab in ankylosing spondylitis
por: Mounach A, et al.
Publicado: (2014) -
Advances in nanomedicine for the treatment of ankylosing spondylitis
por: Xi Y, et al.
Publicado: (2019) -
Serum IL-6 correlates with axial mobility index (Bath Ankylosing Spondylitis Metrology Index) in Brazilian patients with ankylosing spondylitis
por: Rabelo CF, et al.
Publicado: (2018) -
Targeting chondrocytes for arresting bony fusion in ankylosing spondylitis
por: Fenli Shao, et al.
Publicado: (2021)